Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis
Noppacharn Uaprasert1, Peter M Voorhees, Nigel Mackman
1Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. drnoppacharn@yahoo.com
European Journal of Cancer (Oxford, England : 1990)
|April 14, 2010
Summary
Multiple myeloma patients face higher venous thromboembolism (VTE) risks, especially with immunomodulatory drugs. Thromboprophylaxis is advised for these regimens, unlike with bortezomib.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Patients with multiple myeloma exhibit a higher risk of venous thromboembolism (VTE) than the general population.
- Immunomodulatory agents like thalidomide and lenalidomide significantly increase VTE incidence in multiple myeloma, particularly with concurrent high-dose dexamethasone or anthracycline chemotherapy.
Purpose of the Study:
- To review the risk of VTE in multiple myeloma patients treated with different therapeutic agents.
- To highlight the current recommendations for thromboprophylaxis in this patient population.
Main Methods:
- Literature review of studies investigating VTE incidence in multiple myeloma.
- Analysis of the impact of specific drug classes (immunomodulatory agents, proteasome inhibitors) on VTE risk.
- Evaluation of current thromboprophylaxis guidelines.
Main Results:
- Immunomodulatory agents (thalidomide, lenalidomide) are associated with increased VTE risk in multiple myeloma.
- Bortezomib (a proteasome inhibitor) is not linked to an elevated VTE risk, showing low thrombotic complication rates without prophylaxis.
- Thromboprophylaxis is recommended for patients on immunomodulatory agent-based regimens.
Conclusions:
- The mechanisms driving VTE in multiple myeloma patients treated with these agents require further investigation.
- Understanding VTE pathogenesis in multiple myeloma may reveal novel therapeutic targets for prevention and treatment.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...